Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2017 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling, with the three conditions met. Let's analyze the transcript. The question asks: Does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look for instances where management talks about specific counterparties' own expansion plans, and that the company is already embedded in that growth, and that the trajectory is early and large relative to the company. Let's scan the transcript. Management discusses various businesses: Life Sciences, Diagnostics, Dental, Environmental & Applied Solutions, Water Quality. They talk about growth drivers, new products, market trends, etc. They mention specific customers or partners? For example, in the Water Quality section, they mention the CM130 coring monitoring system developed in collaboration with one of the leading dialysis providers in the U.S. That is a specific partner. But does management describe that partner's own trajectory as driving the company's future? They say it's a new product, but they don't describe the partner's expansion plans or scaling. They just mention the collaboration. Another instance: In the Diagnostics section, they talk about Cepheid's growth, but that's their own business. They mention FDA clearance for a test, but not counterparties. In the Life Sciences section, they talk about Pall's innovations, but not specific customers' trajectories. In the Dental section, they talk about new products, but not specific counterparties. In the Environmental & Applied Solutions, they talk about Videojet's service initiatives, but not specific customers. The question is about whether management's forward account is substantially about what counterparties are doing. I don't see that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.